Trevena lands $430M Forest deal, $60M venture round as heart drug heads to PhIIb

John Carroll With its lead drug poised to begin a Phase IIb study for acute heart failure, Trevena grabbed a $ 30 million investment from Forest Laboratories, which also picked up ...

Shire strikes discovery deal in rare diseases with Bill Gates-backed Nimbus

Ryan McBride Shire has nailed down another deal to fuel its growing rare disease unit. The pharma group has tapped the Cambridge, MA-based startup Nimbus Discovery, which will use its ...

Bristol-Myers’ ‘smart bomb’ deal pushes Ambrx 12-month deal tally to $715M

John Carroll Just a month after landing a $ 15 million payday for a deal with Astellas to collaborate on new antibody drug conjugates for cancer, the San Diego-based biotech Ambrx ...

Biotech Symphogen tacks on $53.7M to big venture round after Merck Serono deal

Ryan McBride Symphogen has replenished its coffers with €41 million ($ 53.7 million) as the Danish biotech makes progress with next-generation antibody drugs for treating cancer. ...

AstraZeneca, Aussie biotech outfit ally in $240M-plus discovery deal

Ryan McBride AstraZeneca's partnership spree of the last two months has gone Down Under. As the company shrinks its internal research work force, AstraZeneca ($ AZN) has tapped ...

Elan spurns buyout offer, preps for deal spree

John Carroll Elan's ($ ELN) board of directors has rejected an $ 11.25-per-share bid by Royalty Pharma, sending a message along that it views the offer as far short of what the ...

U.K. goes after GSK for decade-old pay-for-delay deal

Eric Palmer Pay-for-delay deals are disliked by regulators on both sides of the Atlantic. A month after the U.S. Supreme Court heard arguments on the practices, regulators in the U.K. ...

Syros Pharma snags $30M funding deal to target master switches of cancer genes

Ryan McBride With licenses to breaking discoveries from labs affiliated with MIT and Harvard, Syros Pharmaceuticals has raised $ 30 million in a Series A round of financing from top ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS